No Data
No Data
NANO MRNA---The full year financial estimates have been revised, with revenue increasing by 111% compared to the initial forecast, and the loss margin is expected to shrink.
On the 14th, NANO MRNA <4571> announced its consolidated financial results for the second quarter of the fiscal year ending March 2025 (April-September 2024). Revenue decreased by 91.5% year-on-year to 0.007 billion yen, operating loss was 0.373 billion yen (compared to a loss of 0.518 billion yen), recurring loss was 0.382 billion yen (compared to a loss of 0.471 billion yen), and net loss attributable to the parent company's shareholders was 0.518 billion yen (compared to a loss of 0.477 billion yen). Regarding the mRNA pharmaceutical pipeline, RUNX1 is targeted for osteoarthritis.
Nano Mrna: Interim report
Nano Mrna: Financial results briefing materials for the 2nd quarter (interim period) of the fiscal year ending March 31, 2025
Starting lineup, RentRacs, and others.
<142A> Jingib downward revision, current fiscal year operating profit forecast 0.008 billion yen ← 0.24 billion yen <145A> Acquisition of shares of System Em's, which is engaged in development of Elise B system (web system / OA · FA system) and others, and subsidiary <149A> Sinka downward revision, current fiscal year operating profit forecast 0.073 billion yen ← 0.171 billion yen <157A> Establishment of G Monster subsidiary <195A> Rice curry performance forecast revised, current fiscal year operating profit forecast 0.125 billion yen ← 0.32 billion yen electric power A
Nano Mrna: Confirmatory letter.
Nano Mrna: Half Year Report - Term 29 (2024/04/01 - 2025/03/31)
No Data
No Data